Monday, May 24, 2010 12:21:58 PM
By Adam Feuerstein 05/21/10 - 06:00 AM EDT
http://www.thestreet.com/story/10762345/12/13-asco-stocks-presenting-new-clinical-data.html
Drug: Voreloxin
Abstract No. 5002
Indication: ovarian cancer
Clinical Trial: Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.
Presentation Time: Monday, June 7. Oral session.
Notes: Final response rate across three different dosages of Voreloxin was 11% with a median progression-free survival of 84 days.
Sunesis will also be presenting final phase II data from a study of voreloxin in patients with acute myeloid leukemia.
posts are IMHO // either news - with LINK
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
